Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market
Biotricity, a leader in Technology-as-a-Service (TaaS) for healthcare, has launched HeartSecure, a direct-to-consumer heart health screening service.
Heart disease is a major global health issue, with cardiovascular disease causing one death every 1.5 seconds worldwide. In the U.S., 127 million adults have at least one risk factor for heart disease, and it accounts for one in three deaths.
HeartSecure aims to address the long wait times for cardiac screenings by providing an affordable, user-friendly solution. Early detection can reduce the risk of heart attacks and strokes by over 80%.
This service is part of Biotricity's mission to democratize healthcare and create new revenue streams while offering a -time discounted launch offer.
- Launch of HeartSecure, aimed at early detection of heart disease.
- Addresses high demand for accessible and timely cardiac health screening.
- Potential to reduce heart attack and stroke risk by over 80%.
- Provides a user-friendly and affordable solution.
- -time discounted launch offer to attract users.
- Creates new revenue streams for Biotricity.
- Enhances Biotricity's position in the growing home diagnostics market.
- Potential challenge in standing out in a competitive market.
- Relies on consumer adoption and trust, which may take time.
- Initial costs and marketing expenditures could impact short-term profitability.
Insights
Biotricity's introduction of the HeartSecure service is a strategic move into the home diagnostics market, which is on a significant growth trajectory. This market is driven by factors such as the growing prevalence of chronic diseases, aging populations and increasing consumer awareness of proactive health management. By offering a discounted launch, Biotricity is likely to attract early adopters, which may help build a loyal customer base. This initiative aligns well with current trends where consumers are seeking more accessible and cost-effective health solutions. The ease of use and affordability that HeartSecure promises can be a game-changer in the market, likely improving Biotricity's market share and brand visibility.
From a financial perspective, the launch of HeartSecure could potentially unlock new revenue streams for Biotricity. The home diagnostics market's expansion, coupled with the high demand for cardiovascular health services, presents a lucrative opportunity. With cardiovascular diseases being a leading cause of mortality globally, the demand for such products is inherently high. However, investors should also consider the costs associated with launching and marketing a new product and whether these will significantly impact short-term profitability. The company's ability to scale this service effectively and manage operational costs will be critical to realizing long-term financial gains. It’s essential to monitor Biotricity's upcoming financial reports for signs of how well this new venture is performing.
The introduction of a direct-to-consumer cardiac screening service like HeartSecure is a significant step in preventative healthcare. Early detection and intervention are important in managing cardiovascular diseases, which can drastically reduce mortality rates and healthcare costs. The ability to provide timely and accessible screenings helps bridge the gap caused by resource shortages and long wait times for traditional cardiologist appointments. However, the efficacy of such services will depend on the accuracy and reliability of the diagnostic tools used. It will be important for Biotricity to ensure that their technology is robust and meets clinical standards to gain the trust of consumers and healthcare professionals alike.
REDWOOD CITY, CA / ACCESSWIRE / June 12, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announces the highly anticipated launch of its direct-to-consumer heart health screening program, HeartSecure. Someone in the world dies of cardiovascular disease (CVD) every 1.5 seconds. In the U.S. alone, 127 million adults have at least 1 risk factor for heart disease, and 1 out of every 3 deaths is attributed to heart disease. To encourage preventative heart care and help reduce the prevalence of CVD, Biotricty is providing a limited-time discounted launch offer for HeartSecure.
Early detection of heart disease and prompt intervention can slash the risk of heart attack and stroke by over
"At Biotricity, we believe in the power of disruptive innovation to improve lives," says Dr. Waqaas Al-Siddiq, Founder and CEO at Biotricity. "Our user-friendly direct-to-consumer cardiac screening service is about transforming an industry, unlocking new revenue streams, and driving shareholder value. But more than that, HeartSecure is about saving and improving lives by making affordable cardiac screenings accessible to all."
HeartSecure represents a monumental leap forward in cardiac monitoring, providing users with unparalleled convenience, affordability, and peace of mind. By increasing access to heart monitoring and empowering individuals to take control of their cardiac health, Biotricity is helping reshape cardiac care. With HeartSecure, Biotricity isn't just democratizing healthcare-it's revolutionizing lives.
For more information about Biotricity Inc. and its innovative healthcare solutions, please visit www.biotricity.com/investors.
About Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to several risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Investor Relations Contacts
SOURCE: Biotricity, Inc.
View the original press release on accesswire.com
FAQ
What is Biotricity's new service HeartSecure?
When was HeartSecure launched?
How does HeartSecure help in reducing heart attack and stroke risk?
Why is there a need for HeartSecure?
What is the stock symbol for Biotricity?
Is there a special offer available for HeartSecure?
